Where Will Pfizer Be in 3 Years?

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Metsera falls after accepting up to $10 billion sweetened buyout offer from Pfizer

(Reuters) -Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer to end a fierce bidding war between the pharma giant and Danish rival Novo Nordisk.

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration

Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring

Pfizer not only beat expectations last quarter, but also boosted its guidance.
Fierce Biotech

With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its
STAT

The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's also taking on a lot of risk.

Pfizer's move for Metsera adds to busy year of healthcare M&A. But the sector's in a rut.

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million in value and announced this year. M&A, however, has not been enough for what the Goldman analysts say will be a third year of underperformance vs.
Feedback